I Corps: Development of Genome Edited Cancer Vaccines

I Corps：基因组编辑癌症疫苗的开发

• 批准号: 1924656
• 负责人: Kaiming Ye
• 金额: $ 5万
• 依托单位: SUNY at Binghamton
• 依托单位国家: 美国
• 项目类别: Standard Grant
• 财政年份: 2019
• 资助国家: 美国
• 起止时间: 2019-04-01 至 2020-05-31
• 项目状态: 已结题
• 来源: https://www.nsf.gov/awardsearch/showAward?AWD_ID=1924656&HistoricalAwards=false
• 关键词: Corps; Development; Genome; Edited; Cancer

The broader impact/commercial potential of this I-Corps project is to bring a novel cancer immunotherapy vaccine to the market for treating solid and metastatic tumors. Solid tumors exhibit the highest rates of incidence and mortality in the United States for the past few decades. Many of the newest advancements in immunotherapy, including bi-specific antibodies and CAR-T cell therapy have shown minimal effect on solid tumors. The vaccine invented by this group fills the gap by providing a personalized immunotherapy vaccine that can stop or reduce the progression of the cancer and prevent its recurrence. It will save millions of lives by treating those incurable cancers with this newly developed vaccine. The plan is to investigate its customer segments, to discover its market, and to understand its regulatory approval processes. The initial customer discovery will be the focus of the NSF I-Corps Short Course, followed by a market discovery and a strategy to raise funds for bringing the vaccine to the market.This I-Corps project is to commercialize an immunotherapy vaccine that was developed based on a discovery made by this group, where genome edited tumor cells were found to elicit a strong immunogenicity against solid tumors, thereby functioning like a vaccine. The initial animal studies supported the feasibility of this approach. Building upon tremendous advances in cancer immunotherapy and genome editing, this vaccine synergistically combines CRISPR genome editing, vaccinations, and personalized medicine to fully activate a patient's immune system against cancer recurrence. This is the first engineered tumor vaccine that prevents cancer cells from evading the immune system. Unlike conventional cancer therapy, it does not have severe off-target side effects. While cancer vaccines have been explored extensively, their clinical development has seen a long lag phase due to hurdles in regulatory approvals and their adoption into existing therapy regimes. The vaccine developed by this group will overcome these hurdles.This award reflects NSF's statutory mission and has been deemed worthy of support through evaluation using the Foundation's intellectual merit and broader impacts review criteria.

该 I-Corps 项目更广泛的影响/商业潜力是将一种新型癌症免疫治疗疫苗推向市场，用于治疗实体瘤和转移性肿瘤。过去几十年来，实体瘤在美国的发病率和死亡率最高。免疫疗法的许多最新进展，包括双特异性抗体和 CAR-T 细胞疗法，对实体瘤的效果微乎其微。该小组发明的疫苗填补了这一空白，提供了一种个性化免疫治疗疫苗，可以阻止或减少癌症的进展并防止其复发。用这种新开发的疫苗治疗那些无法治愈的癌症将挽救数百万人的生命。该计划旨在调查其客户群、发现其市场并了解其监管审批流程。最初的客户发现将是 NSF I-Corps 短期课程的重点，随后是市场发现和筹集资金以将疫苗推向市场的策略。该 I-Corps 项目旨在将开发的免疫治疗疫苗商业化基于该小组的一项发现，基因组编辑的肿瘤细胞被发现能够引发针对实体瘤的强大免疫原性，从而发挥疫苗的作用。最初的动物研究支持了这种方法的可行性。该疫苗建立在癌症免疫疗法和基因组编辑方面的巨大进步的基础上，协同结合 CRISPR 基因组编辑、疫苗接种和个性化医疗，以充分激活患者的免疫系统，防止癌症复发。这是第一个可以防止癌细胞逃避免疫系统的工程肿瘤疫苗。与传统的癌症治疗不同，它没有严重的脱靶副作用。尽管癌症疫苗已得到广泛探索，但由于监管审批和采用现有治疗方案方面存在障碍，其临床开发经历了很长的滞后阶段。该小组开发的疫苗将克服这些障碍。该奖项反映了 NSF 的法定使命，并通过使用基金会的智力优势和更广泛的影响审查标准进行评估，被认为值得支持。